[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"idiopathic-parkinson-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:idiopathic-parkinson-disease":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,57,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100568408","phase-2-a-phase-2-study-and-open-label-extension-of-neu-411-in-companion-diagnostic-positive-participants-with-early-parkinsons-disease-100568408",false,"NCT06680830","A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)","NEULARK","Inclusion Criteria:\n\n1. Aged 40-80 years at time of screening, inclusive\n2. Diagnosis of clinically established or clinically probable Parkinson's Disease (PD)\n3. LRRK2-driven PD using the investigational companion diagnostic genetic test (CDx)\n4. Modified Hoehn and Yahr (mH\\&Y) of 1 to 2.5\n\nExclusion Criteria:\n\n1. Secondary or atypical parkinsonian syndromes\n2. Uncontrolled diabetes mellitus with hemoglobin A1c (HbA1c) \\>8%\n3. Other significant medical conditions (as determined by medical history, examination, or clinical investigations at screening)\n\nAdditional inclusion and exclusion criteria for the RCP and OLE are outlined in the full study protocol.","ALL","40 Years","80 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the \"leucine-rich repeat kinase 2\" (\"LRRK2\" for short) pathway based on their genetic profile. A DNA test will be used to identify the \"LRRK2-driven\" population with predicted elevation in the LRRK2 pathway.",[28,29,30,31,32],"Parkinson Disease","Parkinson","Idiopathic Parkinson Disease","Early Parkinson Disease (Early PD)","Parkinson Disease, Idiopathic",[34,35,36,37,38,39,15,40,41,42,43],"Early PD","Parkinsons","Parkinsons Disease","Idiopathic Parkinsons Disease","leucine-rich repeat kinase 2","PD","LRRK2","PARK8","de novo Parkinsons disease","Parkinson's disease","RECRUITING","2026-06-29",{"date":47,"type":48},"2026-07-01","ACTUAL",{"date":50,"type":48},"2025-01-17",{"date":52,"type":22},"2028-06",{"name":54,"class":55},"Neuron23 Inc.","INDUSTRY",70,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100594728","reliability-and-validity-study-of-the-turkish-version-of-the-parkinsons-disease-dyskinesia-scale-pdys-26-100594728","NCT07023224","Reliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)","Adaptation Of The Parkinson's Disease Dyskinesia Questionnaire Into Turkish And Its Validity And Reliability In Parkinson's Patient","Inclusion Criteria:\n\n* Being diagnosed with idiopathic Parkinson's disease\n* H\\&Y stage 1-3\n* UPDRS dyskinesia item score ≥1\n* Accepting to participate in the study\n\nExclusion Criteria:\n\n* Diagnosis of atypical-secondary parkinsonism\n* Severe musculoskeletal, neurological and\u002For cardiopulmonary problems that may affect the results of the assessment\n* Mini Mental State Examination score \\\u003C 24",{"count":65,"type":22},130,"OBSERVATIONAL","The aim of this methodological study was to investigate the Turkish validity and reliability of the Parkinson's Disease Dyskinesia Scale (PDYS-26).The scale evaluates choreic dyskinesia.Measures the impact of dyskinesia on activities of daily living in patients with Parkinson's disease.\n\nHypotheses of the Study:\n\n* Parkinson's Disease Dyskinesia Scale (PDYS-26) is reliable in Turkish.\n* Parkinson's Disease Dyskinesia Scale (PDYS-26) is valid in Turkish.\n\nTo determine the validity of dyskinesia;\n\n* Tampa Kinesiophobia Scale,\n* Mini BesTest,\n* Activity Specific Balance Safety Scale (ABC) and\n* Parkinson's Disease Questionnaire-39 will be evaluated.",[30,69,70],"Dyskinesias","Quality of Life",[43,72,73],"Dyskinesia","Parkinson's Disease Dyskinesia Scale","2025-09-16",{"date":76,"type":48},"2025-09-19",{"date":78,"type":48},"2024-11-14",{"date":80,"type":22},"2025-12-01",{"name":82,"class":83},"Izmir Bakircay University","OTHER",2,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100594123","adhesion-and-safety-of-rotigexole-compared-to-neupro-100594123","NCT07015346","Adhesion and Safety of Rotigexole Compared to Neupro®","A Non-inferiority Open-labelled Crossover Randomized Controlled Trial, of Two Arms, to Investigate the Adhesiveness and Safety of Rotigexole 8 mg\u002F24 Hours Transdermal Patch, Manufactured by Eva Pharma, Egypt, Compared to the Innovator Product, Neupro® 8 mg\u002F 24 Hours Transdermal Patch, Manufactured by UCB Pharma S.A., Belgium, After 24 Hours of Application","START","Inclusion Criteria:\n\n1. Male or Female patients aged ≥30 years at Screening\n2. Diagnosed with idiopathic Parkinson's disease with a Hoehn and Yahr stage of II to III.\n3. Patients who have not received dopamine agonists in the past 30 days or are willing to discontinue current dopamine agonist therapy for the duration of the study\n4. Subjects should have a Mini Mental State Examination (MMSE) score of ≥25 at Screening.\n5. Participants who are able to tolerate Rotigotine transdermal patch incremental run-in period for 3 weeks.\n6. Willing to refrain from swimming, bathing or sauna use on assessment days.\n7. Participants should be using a reliable method of contraception (e.g., intrauterine device, barrier methods, condoms) throughout the study and for at least 30 days after the last dose of study medication\n8. Female participants should have a negative pregnancy test at screening, before starting study medication and for at least 30 days after the last dose of study medication\n9. Ability to provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients with a medical history indicating a Parkinsonian syndrome other than idiopathic PD (e.g., drug-induced, post-stroke)\n2. History of significant skin hypersensitivity to adhesives or other transdermal products.\n3. History of or clinical features consistent with atypical parkinsonian syndromes (e.g., multiple system atrophy, progressive supranuclear palsy)\n4. CNS or psychiatric disorders other than idiopathic PD (mild depression or anxiety arising in the context of PD is not exclusionary).\n5. Use of any symptomatic drug for PD other than levodopa, pramipexole, ropinirole, or Rotigotine within 60 days prior to the first dose.\n6. Patients with a history of brain surgery for PD (e.g., pallidotomy, thalamotomy, deep brain stimulation).\n7. Recent exposure to monoamine oxidase type A inhibitors, amphetamines, dopamine-depleting antihypertensive agents, neuroleptics, or antiemetics that block central dopamine activities.\n8. Unstable or clinically significant cardiovascular disease within the last year prior to screening (e.g., arrhythmias, conduction blocks, congestive heart failure.\n9. Concomitant disease or unstable medical condition within 6 months of screening that could interfere with the study or treatment.\n10. Participant has history of or presence of neuroleptic malignant syndrome at screening as assessed by the investigator.\n11. Participant has a current diagnosis of Epilepsy, has a history of seizures, stroke, or transient ischemic attack within 1 year prior to screening\n12. Presence of hepatitis B surface antigen (HBsAg) or positive for total hepatitis B core antibody (HbcAb), or positive hepatitis C (HCV) at screening.\n13. Vaccines other than SARS-CoV-2 vaccine within 28 days prior to the first dose or plans to receive vaccines during the study or within 28 days of the last dose.\n14. History of immunodeficiency disease (e.g., HIV).\n15. Clinically significant abnormalities in laboratory test results at screening, including hepatic and renal panels, complete blood count, chemistry panel, and urinalysis.\n16. Recently unresolved allergies, hypersensitivity, contact dermatitis or an active skin disease.\n17. Participants who have history of alcohol abuse within 6 months before screening as assessed by the investigator.\n18. Pregnant or lactating females","30 Years",{"count":95,"type":22},40,[97],"NA","A non-inferiority open-labelled crossover randomized controlled trial, of two arms, to investigate the adhesiveness and safety of Rotigexole 8 mg\u002F24 hours transdermal patch, manufactured by Eva pharma, Egypt, compared to the innovator product, Neupro® 8 mg\u002F 24 hours transdermal patch, manufactured by UCB Pharma S.A., Belgium, after 24 hours of application",[30],[101,102,103,104,105,106,107],"Rotigexole","Rotigotine","non-inferiority","open label","multicentric","randomized","cross-over","NOT_YET_RECRUITING","2025-08-06",{"date":111,"type":48},"2025-08-07",{"date":113,"type":22},"2025-09-01",{"date":115,"type":22},"2025-10-30",{"name":117,"class":55},"Eva Pharma"]